Paragon Biosciences

Today we announced our acquisition of Epygenix Therapeutics, which accelerates our growth strategy by adding a rare epilepsy franchise to our expanding late-stage pipeline of innovative CNS assets and furthers our commitment to delivering promising treatments to patients with high unmet medical needs. Read more: https://lnkd.in/eghw4kyF  

Central nervous system (CNS) disorders are extremely challenging to treat. The brain’s natural physical and biochemical wall, called the blood-brain barrier, provides it with almost superhuman protection. The better we understand how the brain develops and operates, the more insight we have on how to effectively penetrate the blood-brain barrier to treat neurological disorders. Researchers from the University of Michigan, the Weizmann Institute of Science, and the University of Pennsylvania have developed the first stem cell culture method that produces a full model of the early stages of the human CNS. “Models like this will open doors for fundamental research to understand early development of the human central nervous system and how it could go wrong in different disorders,” said Jianping Fu, University of Michigan professor of mechanical engineering and corresponding author of the study in Nature. In addition, the model could provide critical insight, resulting in better treatment strategies for CNS disorders. Details about the study can be found here: https://lnkd.in/g3Nse6Kx

A Neurology Today article highlights our positive phase 2b D1AMOND study data that will be presented at the American Academy of Neurology (AAN) Annual Meeting in Denver, April 13-18. Read more about this potential therapeutic for Tourette’s syndrome: https://lnkd.in/gDebzxvy

We are excited to share that Harmony Biosciences has been ranked among the top 25 fastest-growing companies in North America by Deloitte Technology’s Fast 500™. At Harmony, our growth and success are testaments to the strength of our business. We are unwavering in our pursuit of bringing novel treatments to people with unmet medical needs and we thank all our team members across the organization for their hard work, dedication and passion for bringing innovation to people living with rare neurological diseases. Read more: https://lnkd.in/eg_7J_zj